News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
200,056 Results
Type
Article (9512)
Company Profile (25)
Press Release (190517)
Multimedia
Podcasts (6)
Webinars (2)
Section
Business (59071)
Career Advice (657)
Deals (11237)
Drug Delivery (25)
Drug Development (29104)
Employer Resources (40)
FDA (4992)
Job Trends (4591)
News (102121)
Policy (8125)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (507)
Accelerated approval (12)
Adcomms (6)
Allergies (64)
Alliances (7926)
ALS (88)
Alzheimer's disease (667)
Antibody-drug conjugate (ADC) (162)
Approvals (5298)
Artificial intelligence (245)
Autoimmune disease (81)
Automation (16)
Bankruptcy (78)
Best Places to Work (4096)
BIOSECURE Act (3)
Biosimilars (114)
Biotechnology (20)
Bladder cancer (125)
Brain cancer (25)
Breast cancer (427)
Cancer (2792)
Cardiovascular disease (216)
Career advice (538)
Career pathing (8)
CAR-T (124)
CDC (9)
Cell therapy (320)
Cervical cancer (21)
Clinical research (27630)
Collaboration (782)
Company closure (1)
Compensation (556)
Complete response letters (11)
COVID-19 (876)
CRISPR (41)
C-suite (320)
Cystic fibrosis (60)
Data (3919)
Denatured (1)
Depression (60)
Diabetes (245)
Diagnostics (1965)
Digital health (19)
Diversity (1)
Diversity, equity & inclusion (10)
Drug discovery (103)
Drug pricing (46)
Drug shortages (11)
Duchenne muscular dystrophy (132)
Earnings (47396)
Editorial (15)
Employer branding (8)
Employer resources (35)
Events (30285)
Executive appointments (442)
FDA (6769)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (12)
Funding (697)
Gene editing (86)
Generative AI (11)
Gene therapy (263)
GLP-1 (459)
Government (1189)
Grass and pollen (4)
Guidances (360)
Healthcare (5311)
HIV (37)
Huntington's disease (16)
IgA nephropathy (45)
Immunology and inflammation (97)
Immuno-oncology (26)
Indications (53)
Infectious disease (1007)
Inflammatory bowel disease (80)
Inflation Reduction Act (5)
Influenza (50)
Intellectual property (77)
Interviews (126)
IPO (7174)
IRA (13)
Job creations (786)
Job search strategy (464)
JPM (20)
Kidney cancer (11)
Labor market (33)
Layoffs (155)
Leadership (5)
Legal (1484)
Liver cancer (40)
Longevity (2)
Lung cancer (409)
Lymphoma (264)
Machine learning (20)
Management (10)
Manufacturing (285)
MASH (78)
Medical device (4210)
Medtech (4232)
Mergers & acquisitions (4624)
Metabolic disorders (602)
Multiple sclerosis (106)
NASH (6)
Neurodegenerative disease (148)
Neuropsychiatric disorders (48)
Neuroscience (1288)
Neurotech (1)
NextGen: Class of 2026 (1484)
Non-profit (1064)
Now hiring (11)
Obesity (275)
Opinion (47)
Ovarian cancer (83)
Pain (78)
Pancreatic cancer (118)
Parkinson's disease (146)
Partnered (6)
Patents (175)
Patient recruitment (215)
Peanut (24)
People (7275)
Pharmaceutical (7)
Pharmacy benefit managers (12)
Phase I (7234)
Phase II (11858)
Phase III (10772)
Pipeline (3322)
Policy (57)
Postmarket research (1068)
Preclinical (2277)
Press Release (27)
Prostate cancer (138)
Psychedelics (8)
Radiopharmaceuticals (92)
Rare diseases (382)
Real estate (912)
Recruiting (16)
Regulatory (7337)
Reports (16)
Research institute (513)
Resumes & cover letters (111)
Rett syndrome (23)
RNA editing (4)
RSV (44)
Schizophrenia (80)
Series A (100)
Series B (96)
Service/supplier (3)
Sickle cell disease (63)
Special edition (8)
Spinal muscular atrophy (91)
Sponsored (10)
Startups (638)
State (1)
Stomach cancer (7)
Supply chain (55)
Tariffs (19)
The Weekly (5)
Vaccines (408)
Venture capital (33)
Weight loss (178)
Women's health (33)
Worklife (8)
Date
Today (78)
Last 7 days (207)
Last 30 days (1145)
Last 365 days (16714)
2026 (1138)
2025 (16920)
2024 (14759)
2023 (14315)
2022 (16776)
2021 (16234)
2020 (15541)
2019 (12785)
2018 (9784)
2017 (9333)
2016 (7966)
2015 (9632)
2014 (7086)
2013 (5215)
2012 (5911)
2011 (6161)
2010 (5233)
Location
Africa (220)
Alabama (17)
Alaska (2)
Arizona (82)
Arkansas (5)
Asia (12763)
Australia (2208)
California (6013)
Canada (1442)
China (553)
Colorado (236)
Connecticut (307)
Delaware (243)
Europe (31142)
Florida (653)
Georgia (156)
Hawaii (3)
Idaho (13)
Illinois (443)
India (27)
Indiana (240)
Iowa (11)
Japan (293)
Kansas (61)
Kentucky (17)
Louisiana (11)
Maine (42)
Maryland (551)
Massachusetts (4334)
Michigan (111)
Minnesota (284)
Mississippi (3)
Missouri (65)
Montana (11)
Nebraska (6)
Nevada (69)
New Hampshire (34)
New Jersey (1690)
New Mexico (6)
New York (1465)
North Carolina (698)
North Dakota (3)
Northern California (2994)
Ohio (137)
Oklahoma (5)
Oregon (10)
Pennsylvania (1050)
Puerto Rico (4)
Rhode Island (18)
South America (325)
South Carolina (15)
Southern California (2281)
Tennessee (74)
Texas (865)
United States (20287)
Utah (131)
Virginia (137)
Washington D.C. (34)
Washington State (486)
West Virginia (2)
Wisconsin (87)
200,056 Results for "6".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
December 10, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine
December 15, 2025
·
2 min read
FDA
6 FDA Decisions To Watch in Q1 2026
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.
January 12, 2026
·
8 min read
·
Tristan Manalac
Press Releases
Lyric Bio, Inc. Closes $6.6 Million Seed Financing To Revolutionize Donor-Derived Therapeutics
December 3, 2025
·
3 min read
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million
November 14, 2025
·
31 min read
Press Releases
Cartesian Therapeutics Announces New Employment Inducement Grants - January 6, 2026
January 6, 2026
·
1 min read
Press Releases
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
December 29, 2025
·
4 min read
Press Releases
Gynecology Drugs Market Size to Reach USD 112.6 Billion by 2034 Rising Gynecological Disorders and Health Awareness Drive Market Growth
The global gynecology drugs market size is forecasted to reach around USD 112.6 billion by 2034, increasing from USD 69.79 billion in 2024 and representing a remarkable CAGR of 4.9% from 2025 to 2034.
October 16, 2025
·
1 min read
Layoffs
Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs
This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer, Bristol Myers Squibb, Novartis and Pfizer have also made noteworthy cuts.
September 18, 2025
·
9 min read
·
Angela Gabriel
1 of 20,006
Next
